Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Aspirin use and risk of colorectal cancer according to BRAF mutation status

This week's issue of the Journal of the American Medical Association investigates the aspirin use and risk of colorectal cancer according to BRAF mutation status.

News image

Aspirin use reduces the risk of colorectal carcinoma.

Experimental evidence implicates a role of RAF kinases in up-regulation of prostaglandin-endoperoxide synthase 2, suggesting that BRAF-mutant colonic cells might be less sensitive to the antitumor effects of aspirin than BRAF–wild-type neoplastic cells.

Dr Reiko Nishihara and colleagues examined whether the association of aspirin intake with colorectal cancer risk differs according to status of tumor BRAF oncogene mutation.

The team collected biennial questionnaire data on aspirin use and followed up participants in the Nurses' Health Study and the Health Professionals Follow-up Study until 2006, for cancer incidence and until 2012, for cancer mortality.

Duplication-method Cox proportional cause-specific hazards regression for competing risks data was used to compute hazard ratios for colorectal carcinoma incidence according to BRAF mutation status.

The team's main outcomes and measures included incidence of colorectal cancer cases according to tumor BRAF mutation status.

Regular aspirin use was associated with lower BRAF–wild-type cancer risk
Journal of the American Medical Association

Among 127,865 individuals, with 3,165,985 person-years of follow-up, the team identified 1226 incident rectal and colon cancers with available molecular data.

Compared with nonuse, regular aspirin use was associated with lower BRAF–wild-type cancer risk.

The team observed this association irrespective of status of tumor PTGS2 expression or PIK3CA or KRAS mutation.

In contrast, regular aspirin use was not associated with a lower risk of BRAF-mutated cancer.

Compared with no aspirin use, aspirin use of more than 14 tablets per week was associated with a lower risk of BRAF–wild-type cancer.

The research team found that the relationship between the number of aspirin tablets per week and colorectal cancer risk differed significantly by BRAF mutation status.

Dr Nishihara's team concludes, "Regular aspirin use was associated with lower risk of BRAF–wild-type colorectal cancer but not with BRAF-mutated cancer risk."

"These findings suggest that BRAF-mutant colon tumor cells may be less sensitive to the effect of aspirin."

"Given the modest absolute risk difference, further investigations are necessary to determine clinical implications of our findings."

JAMA 2013; 309(24): 2563-2571
26 June 2013

Go to top of page Email this page Email this page to a colleague

 30 October 2014

Advanced search
 30 October 2014 
Cirrhosis in women
 30 October 2014 
Costs in newly diagnosed patients with chronic constipation
 30 October 2014 
Constipation and colorectal cancer
 29 October 2014 
IBS in primary care
 29 October 2014 
Sensorimotor activity in functional dyspepsia
 29 October 2014 
Quality of life after infection with E. coli
 28 October 2014 
Increased bile acid synthesis in IBS-diarrhea
 28 October 2014 
Risk factor for smaller final height in Crohn's
 28 October 2014 
Successful radiofrequency ablation for Barrett’s
 27 October 2014 
Celiac disease and type 1 diabetes
 27 October 2014 
Gluten awareness among chefs
 27 October 2014 

PPI-responsive esophageal eosinophilia

 24 October 2014 
Olmesartan-associated enteropathy
 24 October 2014 
Opioid use in IBD
 24 October 2014 
NSAIDs and Barrett's risk
 23 October 2014 
Outcomes in hospitalized patients with GI bleeding
 23 October 2014 
Thiopurines and colorectal cancer risk in IBD
 23 October 2014 
Advancing the field of functional GI disorders
 22 October 2014 
Early-TIPSS placement prevents rebleeding
 22 October 2014 
Liver fibrosis prognostic biomarkers in type-2 diabetes
 22 October 2014 
H pylori eradication with multiple drug resistance
 21 October 2014 
Alcohol and Barrett's
 21 October 2014 
Scoring systems for critically ill cirrhotic patients
 21 October 2014 
Aspirin and NAFLD
 20 October 2014 
Drug resistant H pylori eradication
 20 October 2014 
Adalimumab in secondary loss of response in Crohn's
 20 October 2014 
Omega-3 and colorectal cancer
 17 October 2014 
Colorectal testing utilization
 17 October 2014 
Tumor necrosis factor-alpha inhibitors and pregnancy in IBD
 17 October 2014 
Fecal microbiota composition in postinfectious IBS
 16 October 2014 
Risk of Barrett's esophagus
 16 October 2014 
Aspirin tablets and colorectal tumours
 16 October 2014 
Economic impact of IBS
 15 October 2014 
Preparation for surgery in Crohn's
 15 October 2014 
Achieving competency at colonoscopy
 15 October 2014 
Bowel preparations
 14 October 2014 
Colorectal testing utilization in commercially insured US adults
 14 October 2014 
Sustained response to infliximab
 14 October 2014 
IBD management during pregnancy
 13 October 2014 
Predicting PPI response in GERD-related cough
 13 October 2014 
Probiotics in IBS
 13 October 2014 
Use of azathioprine in IBD
 10 October 2014 
Liver injury from herbals and dietary supplements
 10 October 2014 
NAFLD in the Veterans Administration population
 10 October 2014 
Predictors for cecal insertion time
 09 October 2014 
Methotrexate-related liver disease and metabolic syndrome
 09 October 2014 
Biomarkers of acetaminophen overdose patients
 09 October 2014 
Postoperative adhesions in digestive surgery
 08 October 2014 
Gluten introduction in high risk children
 08 October 2014 
Vitamin D and HCC
 08 October 2014 
Feeding intervention in celiac disease infants
 07 October 2014 
Infliximab in pediatric perianal Crohn's
 07 October 2014 
Omega-3 and NAFLD
 07 October 2014 
Endoscopic submucosal dissection in the colorectum 
 06 October 2014 
Clinical indications for computed tomographic colonography
 06 October 2014 
Certolizumab pegol in the treatment of Crohn's
 06 October 2014 
Costs of telaprevir therapy for Hep C
 03 October 2014 
Depression and liver transplantation
 03 October 2014 
Orange juice intake during bowel preparation
 03 October 2014 
HCV and diabetes

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us